LA Pharmacie Centrale DE Tunisie Pharmaceutical Import Profile — Tunisia (DGFT 2022–2026)

Name: LA Pharmacie Centrale DE Tunisie Pharmaceutical Import Records from India — 5 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

LA Pharmacie Centrale DE Tunisie — Pharmaceutical Importer Profile (2026) | 5 Products, $1.8M Trade | TransData Nexus

LA Pharmacie Centrale DE Tunisie

Pharmaceutical Importer · Tunisia · Tuberculosis Medications Focus · $1.8M Total Trade · DGFT Verified

LA Pharmacie Centrale DE Tunisie is a pharmaceutical importer based in Tunisia with a total trade value of $1.8M across 5 products in 3 therapeutic categories. Based on 36 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. LA Pharmacie Centrale DE Tunisie sources from 11 verified Indian suppliers, with Macleods Pharmaceuticals Limited accounting for 24.2% of imports.

LA Pharmacie Centrale DE Tunisie — Import Portfolio & Supplier Network

LA Pharmacie Centrale DE Tunisie import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to LA Pharmacie Centrale DE Tunisie?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$642.4K	50	24.2%
Dr.reddy's Laboratories Limited	$595.1K	17	22.4%
Mylan Laboratories Limited

What Formulations Does LA Pharmacie Centrale DE Tunisie Import?

Formulation	Value	Ships
Myhep all sofo velp TAB 400 100MG 28bt ly my 28 s	$150.0K	3
Drugs and pharmaceuticals harmless	$129.2K	5
Myhep all sofo/velp TAB 400/100MG 28bt ly my packs	$114.7K	3
Lopinavir 200MG / ritonavir 50MG 120 TAB	$100.0K	2
Drugs and pharmaceuticals harmless medicines rifampicin capsules BP 300 MG	$94.0K	3
Isoflurane 100 ML other desc.as per	$65.0K	2
Fluphenazine decanoate injection USP	$52.1K	2
Efavirenz 600MG/emtricitabine 200MG/tenofovir disoproxil fumarate 300MG tabletsbno:bed82307a md.10/23 ed.9/25 ps:1x30s	$50.0K	2
Redditux 100MG/10ML SOL.INJ.p.ref.bt 1	$50.0K	1
Redditux 500MG/50ML SOL,INJ.p.ref.bt 1	$50.0K	1
Redditux 500MG 50ML qty 1800	$50.0K	1
Redditux 100MG 10ML qty 2600	$50.0K	1
Redditux 500MG/50ML SOL. INJ.p.perf.bt	$50.0K	1
Redditux 500MG/50ML SOL. INJ.p.perf.	$50.0K	1
Redditux 500MG/50ML(qty:1800 vials)	$50.0K	1

LA Pharmacie Centrale DE Tunisie imports 94 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rifampicin	Advanced Antibiotics	$800.0K	16	0.1%	3
2	Isoniazid	Tuberculosis Medications	$600.0K	12	0.0%	4
3	Ethambutol	Tuberculosis Medications	$150.0K	3	0.0%	4
4	Pyrazinamide	Tuberculosis Medications	$150.0K	3	0.0%	2
5	Mefloquine	Antimalarial & Antiparasitic	$76.1K	2	3.1%	4

LA Pharmacie Centrale DE Tunisie imports 5 pharmaceutical products across 3 categories into Tunisia totaling $1.8M.

LA Pharmacie Centrale DE Tunisie — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

LA Pharmacie Centrale de Tunisie (PCT) is a state-owned enterprise operating under the Ministry of Health, established on June 27, 1938. Headquartered in Tunis, Tunisia, PCT serves as the central procurement and distribution entity for pharmaceutical products within the country. Its primary mission is to ensure the continuous supply of medications and medical supplies to public and private healthcare institutions, including hospitals, clinics, and pharmacies. PCT plays a pivotal role in maintaining the stability and accessibility of Tunisia's healthcare system by managing the national stock of pharmaceuticals and facilitating their equitable distribution. (phct.com.tn)

2Distribution Network

PCT operates a comprehensive distribution network with multiple centers strategically located across Tunisia. The central warehouse, known as the Cité des Médicaments in Ben Arous, serves as the main hub for storage and distribution. Additional distribution centers are situated in Sousse, Sfax, Gafsa, and Médenine, each catering to the specific needs of their respective regions. This extensive network enables PCT to effectively manage and deliver pharmaceutical products nationwide, ensuring timely and efficient supply to various healthcare facilities. (phct.com.tn)

3Industry Role

As the national government entity responsible for pharmaceutical procurement and distribution, PCT functions as the primary wholesaler in Tunisia's pharmaceutical supply chain. It acts as the central purchasing body for the government, sourcing medications and medical supplies both domestically and internationally. PCT's role is crucial in maintaining the stability of the pharmaceutical market, regulating drug prices, and ensuring the availability of essential medicines across the country. By centralizing procurement, PCT aims to achieve economies of scale, negotiate favorable pricing, and streamline the distribution process to meet the healthcare needs of the Tunisian population. (phct.com.tn)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — LA Pharmacie Centrale DE Tunisie

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

PCT's sourcing strategy exhibits a significant concentration on a select group of Indian pharmaceutical suppliers. The top five suppliers—MACLEODS PHARMACEUTICALS LIMITED, DR.REDDY'S LABORATORIES LIMITED, MYLAN LABORATORIES LIMITED, S.D.PHARMACEUTICALS, and MANEESH PHARMACEUTICALS LIMITED—collectively account for approximately 97% of PCT's total imports from India. This high level of concentration suggests a strategic approach to procurement, potentially leveraging established relationships and favorable pricing agreements. However, such dependency also poses risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by these suppliers. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

PCT's reliance on a concentrated group of Indian suppliers for its pharmaceutical imports raises concerns about supply chain resilience. The limited number of suppliers increases vulnerability to disruptions that could affect the timely availability of essential medications. To bolster resilience, PCT could consider identifying and establishing relationships with additional suppliers, both within India and internationally, to diversify its sourcing strategy. Additionally, evaluating the regulatory compliance and manufacturing standards of current suppliers is essential to ensure consistent product quality and mitigate potential risks associated with non-compliance.

Importing Pharmaceuticals into Tunisia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Tunisia

1Regulatory Authority & Framework

In Tunisia, the Ministry of Health is the primary regulatory authority overseeing the pharmaceutical sector. The Ministry is responsible for formulating policies, regulating drug imports, and ensuring the safety and efficacy of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Pharmaceutical Code, which outlines the requirements for marketing authorization, importation procedures, and quality control standards. The marketing authorization pathway for Indian generics involves submitting a dossier to the Ministry of Health, demonstrating compliance with Tunisian regulations, and obtaining approval before products can be marketed and distributed within the country.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Tunisia mandate that all imported medications possess a valid marketing authorization issued by the Ministry of Health. Additionally, imported products must be accompanied by a Good Manufacturing Practice (GMP) certificate recognized by the Ministry, ensuring that manufacturing processes meet international quality standards. Wholesale distribution authorization is also required for entities involved in the distribution of pharmaceutical products, ensuring that they operate in compliance with Tunisian regulations and maintain the integrity of the supply chain.

LA Pharmacie Centrale DE Tunisie — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

PCT's focus on importing tuberculosis medications, advanced antibiotics, and antimalarial and antiparasitic drugs aligns with Tunisia's public health priorities. The high prevalence of tuberculosis and malaria in certain regions necessitates a steady supply of effective treatments. Advanced antibiotics are essential for managing complex infections, while antimalarial and antiparasitic drugs are critical for controlling vector-borne diseases. This strategic product selection ensures that PCT addresses the most pressing health challenges faced by the Tunisian population.

2Sourcing Profile

PCT's sourcing strategy emphasizes the procurement of generic drugs, particularly in the therapeutic areas of tuberculosis, advanced antibiotics, and antimalarial and antiparasitic treatments. The focus on generic formulations allows for cost-effective procurement, making essential medications more accessible to the population. India's robust pharmaceutical manufacturing sector, known for producing high-quality generics, aligns well with PCT's procurement needs, ensuring a reliable supply of effective treatments.

3Market Positioning

Seller's Guide — How to Become a Supplier to LA Pharmacie Centrale DE Tunisie

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with PCT, especially if they can offer competitive pricing, reliable delivery schedules, and adherence to international quality standards. Diversifying PCT's supplier base could enhance supply chain resilience and mitigate risks associated with over-reliance on a limited number of suppliers. Indian exporters should focus on building relationships with PCT, understanding its procurement processes, and ensuring compliance with Tunisian regulatory requirements to capitalize on these opportunities.

2Requirements & Qualifications

Indian exporters aiming to supply PCT must ensure that their products have valid marketing authorizations from the Ministry of Health in Tunisia. They must also provide GMP certificates recognized by the Ministry, demonstrating compliance with international manufacturing standards. Additionally, products must meet labeling requirements in Arabic and French, include necessary batch testing and stability data, and comply with serialization mandates to ensure traceability and prevent counterfeit products.

3How to Approach

Frequently Asked Questions — LA Pharmacie Centrale DE Tunisie

What products does LA Pharmacie Centrale DE Tunisie import from India?

LA Pharmacie Centrale DE Tunisie imports 5 pharmaceutical products across 3 categories. Top imports: Rifampicin ($800.0K), Isoniazid ($600.0K), Ethambutol ($150.0K), Pyrazinamide ($150.0K), Mefloquine ($76.1K).

Who supplies pharmaceuticals to LA Pharmacie Centrale DE Tunisie from India?

LA Pharmacie Centrale DE Tunisie sources from 11 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (24.2% of imports, $642.4K).

What is LA Pharmacie Centrale DE Tunisie's total pharmaceutical import value?

LA Pharmacie Centrale DE Tunisie's total pharmaceutical import value from India is $1.8M, based on 36 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does LA Pharmacie Centrale DE Tunisie focus on?

LA Pharmacie Centrale DE Tunisie imports across 3 categories. The largest: Tuberculosis Medications (50.7%), Advanced Antibiotics (45.0%), Antimalarial & Antiparasitic (4.3%).

Get Full LA Pharmacie Centrale DE Tunisie Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.